Rare inherited disorders of fibrinogen

Haemophilia

Volumn 14, Issue 6, 2008, Pages 1151-1158

  Acharya, Suchitra S ^a   Dimichele, D M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Bleeding; Congenital afibrinogenemia; Dysfibrinogenemia; Fibrinogen genes; Hypofibrinogenemia; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIFIBRINOLYTIC AGENT; DNA; ESTROGEN; FIBRIN GLUE; FIBRINOGEN; FIBRINOGEN CONCENTRATE; FRESH FROZEN PLASMA; HAEMOCOMPLETTAN; HEPARIN; LEPIRUDIN; MESSENGER RNA; PROGESTERONE; RNA; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

AFIBRINOGENEMIA; ARTICLE; BLEEDING; BLOOD CLOTTING TEST; BLOOD TRANSFUSION; CLINICAL FEATURE; CRYOPRECIPITATE; DYSFIBRINOGENEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOGEN DEFECT; GENE MUTATION; GENOTYPE; HEREDITARY FIBRINOGEN DISORDER; HUMAN; HYPOFIBRINOGENEMIA; IMMUNOASSAY; LABORATORY DIAGNOSIS; MENORRHAGIA; MISSENSE MUTATION; PATHOGENESIS; PHENOTYPE; POSTOPERATIVE HEMORRHAGE; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; RARE DISEASE; RNA STABILITY; THROMBOSIS;

ADULT; AFIBRINOGENEMIA; BLOOD COAGULATION; COAGULANTS; FACTOR VIII; FEMALE; FIBRINOGEN; GENOTYPE; HEMORRHAGE; HUMANS; INFANT, NEWBORN; IRAN; ITALY; MALE; MEDLINE; MUTATION; NORTH AMERICA; PHENOTYPE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PRENATAL DIAGNOSIS; RARE DISEASES;

EID: 56049098385     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01831.x     Document Type: Article

References (36)

1. Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Ann N Y Acad Sci 2001; 936: 11-30.
2. Rabe F, Salomon E. Uber-faserstoffmangel in Blute bei einem Falle von Haemophilie. Arch Int Med 1920; 95: 2.
3. Werder E. Congenital afibrinogenemia. Helv Paediatr Acta 1963; 18: 208-29.
4. Martinez J, Palascak J, Peters C. Functional and metabolic properties of human asialofibrinogen. J Lab Clin Med 1977; 89: 367-77.
5. Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004; 104: 1243-52.
6. Lak M, Keihani M, Elahi F, Peyvandi F, Mannucci PM. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol 1999; 107: 204-6.
7. Acharya SS, Coughlin A, Dimichele DM, North American Rare Bleeding Disorder Study Group. Rare Bleeding Disorder Registry: Deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004; 2: 248-56.
8. Peyvandi F, Duga S, Akhavan S, Mannucci PM. Rare coagulation deficiencies. Haemophilia 2002; 8: 308-21.
9. Asselta R, Duga S, Tenchini ML. The molecular basis of quantitative fibrinogen disorders. J Thromb Haemost 2006; 4: 2115-29.
10. Kent WJ, Sugnet CW, Furey TS, et al. The Human Genome Browser at UCSC. Genome Res 2002; 12: 996-1006.
11. Neerman-Arbaz M. Molecular basis of fibrinogen deficiency. Pathophysiol Haemost Thromb 2006; 35: 187-98.
12. al-Mondhiry H, Ehmann WC. Congenital afibrinogenemia. Am J Hematol 1994; 46: 343-7.
13. Kobayashi T, Asahina T, Maehara K, Itoh M, Kanayama N, Terao T. Congenital afibrinogenemia with successful delivery. Gynecol Obstet Invest 1996; 42: 66-9.
14. Suh TT, Holmback K, Jensen NJ, et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 1995; 9: 2020-33.
15. Girolami A, Ruzzon E, Tezza F, Scandellari R, Vettore S, Girolami B. Arterial and venous thrombosis in rare congenital bleeding disorders: A critical review. Haemophilia 2006; 12: 345-51.
16. Dupuy E, Soria C, Molho P, et al. Embolized ischemic lesions of toes in an afibrinogenemic patient: Possible relevance to in vivo circulating thrombin. Thromb Res 2001; 102: 211-9.
17. Mosesson MW. Antithrombin I. Inhibition of thrombin generation in plasma by fibrin formation. Thromb Haemost 2003; 89: 9-12.
18. Ni H, Denis CV, Subbarao S, et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000; 106: 385-92.
19. Peyvandi F, Haertel S, Knaub S, Mannucci PM. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. J Thromb Haemost 2006; 4: 1634-7.
20. Rubbia-Brandt L, Neerman-Arbez M, Rougemont AL, MaléPJ, Spahr L. Fibrinogen gamma375 arg->trp mutation (fibrinogen Aguadilla) causes hereditary hypofibrinogenemia, hepatic endoplasmic reticulum storage disease and cirrhosis. Am J Surg Pathol 2006; 30: 906-11.
21. Medicina D, Fabbretti G, Brennan SO, George PM, Kudryk B, Callea F. Genetic and immunological characterization of fibrinogen inclusion bodies in patients with hepatic fibrinogen storage and liver disease. Ann NY Acad Sci 2001; 936: 522-5.
22. Hans M, Biot F. A database for human fibrinogen variants. Ann N Y Acad Sci 2001; 936: 89-90.
23. Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995; 73: 151-61.
24. Siebenlist KR, Mosesson MW, Meh DA, DiOrio JP, Albrecht RM, Olson JD. Coexisting dysfibrinogenemia (gammaR275C) and factor V Leiden deficiency associated with thromboembolic disease (fibrinogen Cedar rapids). Blood Coagul Fibrinolysis 2000; 11: 293-304.
25. Hayes T. Dysfibrinogenemia and thrombosis. Arch Pathol Lab Med 2002; 126: 1387-90.
26. Lefkowitz JB, DeBoom T, Weller A, Clarke S, Lavrinets D. Fibrinogen Longmont: A dysfibrinogenemia that causes prolonged clot-based test results only when using an optical detection method. Am J Hematol 2000; 63: 149-55.
27. Neerman-Arbez M, de Moerloose P, Bridel C, et al. Mutations in the fibrinogen A alpha gene account for the majority of cases of congenital afibrinogenemia. Blood 2000; 96: 149-52.
28. Vu D, de Moerloose P, Batorova A, Lazur J, Palumbo L, Neerman-Arbez M. Hypofibrinogenaemia caused by a novel FGG missense mutation (W253C) in the gamma chain globular domain impairing fibrinogen secretion. J Med Genet 2005; 42: E57.
29. Roberts HR, Stinchcombe TE, Gabriel DA. The dysfibrinogenaemias. Br J Haematol 2001; 114: 249-57.
30. McDonagh J. Dysfibrinogenemia and other disorders of fibrinogen structure or function. In: Colman R, Hirsh J, Marder V, Clowes A, George J, eds. Hemostasis and Thrombosis, 4th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2001: 855-92.
31. Kreuz W, Meili E, Peter-Salonen K, et al. Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency. Transfus Apher Sci 2005; 32: 247-53.
32. Santagostino E, Mancuso ME, Morfini M, et al. Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: Dosing, pharmacokinetics and clinical efficacy. Haematologica 2006; 91: 634-9.
33. Rizk DE, Kumar RM. Congenital afibrinogenemia: Treatment of excessive menstrual bleeding with continuous oral contraceptive. Am J Hematol 1996; 52: 237-8.
34. Ra'anani P, Levi Y, Varon D, Gitel S, Martinowitz U. Congenital afibrinogenemia with bleeding, bone cysts and antibodies to fibrinogen. Harefuah 1991; 121: 291-3.
35. Schuepbach RA, Meili EO, Schneider E, Peter U, Bachli EB. Lepirudin therapy for thrombotic complications in congenital afibrinogenaemia. Thromb Haemost 2004; 91: 1044-6.
36. Kreuz W, Meili E, Peter-Salonen K, et al. Pharmacokinetic properties of a pasteurised fibrinogen concentrate. Transfus Apher Sci 2005; 32: 239-46.